COMMUNIQUÉS West-GlobeNewswire

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
20/04/2026
AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector [...]
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
20/04/2026
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, [...]
Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK’s Knowledge Quarter
20/04/2026
Boehringer is expanding its global Computational Innovation footprint with a new center dedicated to AI and machine learning (ML) in the UK Establishing a presence in King’s Cross, London, places Boehringer at the heart [...]
Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results
20/04/2026
Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes U.S. Roadside drug testing market projected to reach $1.62 billion by 2030 [...]
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
20/04/2026
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical [...]
Atsena Therapeutics Receives Data Monitoring Committee Recommendation to Proceed with Pivotal Part C Cohort of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
20/04/2026
Patient screening to begin this month DURHAM, N.C., April 20, 2026 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse [...]
Axe Compute Unveils Compute Reserve Dashboard, Giving Investors a Unified View of Its NASDAQ Stock and Operational Strategic Compute Reserve
20/04/2026
Purpose-built for the neocloud era: a unified view of Axe Compute's NASDAQ equity and its Strategic Compute Reserve (SCR), the operational reserve that funds enterprise access to 435,000+ GPUs across 200+ global [...]
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
20/04/2026
Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on [...]
Vystar Enters into Binding Letter of Intent to Acquire 50% Interest in R3alm Inc.
20/04/2026
A Compliance-Focused AI and Web3 Financial Ecosystem Proposed Transaction Includes Joint Development Framework, Vystar Series B Consideration, and Strategic Alignment Around the R3EQ Ecosystem ■ ■ ■ Vystar to Receive [...]
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
20/04/2026
CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
20/04/2026
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live biotherapeutics in [...]
KFSH Joins C3 Davos of Healthcare™ 2026 in Sunnyvale, California, as a Global Strategic Partner
20/04/2026
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) will participate as a Global Strategic Partner at the C3 Davos of Healthcare™ Silicon Valley Summit, [...]
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
20/04/2026
WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the pricing of its [...]
Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
20/04/2026
LOUISVILLE, Colo., April 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, [...]
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
20/04/2026
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI’s Pimozide Tablets is the generic [...]
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
20/04/2026
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live biotherapeutics in [...]
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
20/04/2026
SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
20/04/2026
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026 A non-invasive topical [...]
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
20/04/2026
Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026 A non-invasive topical treatment for diabetic macular edema (DME) has the [...]

Pages